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Abstract
Background: There is evidence of functional growth hormone (GH) deficiency, expressed by
means of low insulin-like growth factor 1 (IGF-1) serum levels, in a subset of fibromyalgia patients.
The efficacy of GH versus placebo has been previously suggested in this population. We
investigated the efficacy and safety of low dose GH as an adjunct to standard therapy in the
treatment of severe, prolonged and well-treated fibromyalgia patients with low IGF-1 levels.
Methods: Twenty-four patients were enrolled in a randomized, open-label, best available care-
controlled study. Patients were randomly assigned to receive either 0.0125 mg/kg/d of GH
subcutaneously (titrated depending on IGF-1) added to standard therapy or standard therapy alone
during one year. The number of tender points, the Fibromyalgia Impact Questionnaire (FIQ) and
the EuroQol 5D (EQ-5D), including a Quality of Life visual analogic scale (EQ-VAS) were assessed
at different time-points.
Results: At the end of the study, the GH group showed a 60% reduction in the mean number of
tender points (pairs) compared to the control group (p < 0.05; 3.25 ± 0.8 vs. 8.25 ± 0.9). Similar
improvements were observed in FIQ score (p < 0.05) and EQ-VAS scale (p < 0.001). There was a
prompt response to GH administration, with most patients showing improvement within the first
months in most of the outcomes. The concomitant administration of GH and standard therapy was
well tolerated, and no patients discontinued the study due to adverse events.
Conclusion: The present findings indicate the advantage of adding a daily GH dose to the standard
therapy in a subset of severe fibromyalgia patients with low IGF-1 serum levels.
Trial Registration: NCT00497562 (ClinicalTrials.gov).
Background
Fibromyalgia is a common syndrome of non-articular ori-
gin, characterized basically by fatigue and widespread
musculoskeletal pain, along with tiredness and sleep dis-
turbances. Pain in at least 11 of 18 trigger point sites on
digital palpation is the only condition required to fulfil
the American College of Rheumatology (ACR) criteria for
fibromyalgia [1]. It is thought that fibromyalgia affects
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between 2.4–3.4% of the adult population, mainly
women [2,3].
The cause of fibromyalgia is not known. However, the
identification of this syndrome as a single clinical entity
has improved the knowledge of its pathophysiology.
There is evidence that the syndrome is influenced by psy-
chiatric conditions such as anxiety or depression [4].
Additionally, reduced levels of biogenic amines, increased
concentrations of excitatory neurotransmitters (both in
the central nervous system nuclea and the medullary dor-
sal horn) [5], and alterations of the autonomic nervous
system and hypothalamic-pituitary-adrenal (HPA) axis
have also been described [6].
There is some evidence of functional GH deficiency,
expressed as low insulin-like growth factor 1 (IGF-1)
serum levels, in a subset of fibromyalgia patients [7].
There is a marked decrease in spontaneous integrated GH
secretion [8]. Normal pituitary responsiveness to exoge-
nously administered growth hormone releasing hormone
(GHRH) is counteracted by hypersomatostatinemia, as
evidenced by the pyridostigmine test [9]. Futhermore,
serum GH together with normal/low IGF-1 levels have
been found elevated fibromyalgia syndrome, suggesting a
GH resistance, and mediating a pro-inflammatory state
responsible in part for the pain suffered by these patients
[10].
Current consensus based on clinical trials establishes that
the best available fibromyalgia treatment should include
drugs, rehabilitation and psychological support. Thera-
pies with proven efficacy in fibromyalgia includes tricyclic
antidepressants, selective serotonin reuptake inhibitors
(SSRI), and opioid analgesics [11]. Regarding fibromyal-
gia patients with low IGF-1 levels, GH administration
demonstrated efficacy and a good tolerability profile in a
placebo-controlled study [12]. Although other studies
allowed the presence of other medications, no clinical tri-
als have been conducted with GH as an adjuvant agent
added to homogeneous active treatment in the manage-
ment of severe and prolonged fibromyalgia with low IGF-
1 levels so far.
Methods
Patients and study design
Women greater than 18 years old with severe fibromyalgia
and abnormally low IGF-1 levels included in an exercise
rehabilitation and psychological program and stable
under standard intensive treatment for at least 6 months
participated in this prospective, randomized, open-label,
best available treatment-controlled clinical trial. All
patients fulfilled the 1990 ACR diagnostic criteria [1] and
had an IGF-1 level <250 ng/mL (or 1 standard deviation
bellow the mean value corresponding to age and gender
according to laboratory reference values). Other inclusion
criteria were duration of fibromyalgia for 1 year or greater,
pain in at least 16 (8 bilateral) of the 18 trigger points and
a score in the Fibromyalgia Impact Questionnaire (FIQ) ≥
75.
Exclusion criteria were as follows: Disabling physical or
mental status; previous or current malignancies, either
active or inactive; intracranial space occupying lesion; any
relevant endocrine disorder including diabetes mellitus;
history of another pituitary disorder; previous treatment
with growth hormone; other systemic or joint inflamma-
tory rheumatic conditions; and known to be hypersensi-
tive to somatropin or any of the excipients. Pregnant
women, nursing mothers, or women with childbearing
potential not using adequate contraceptive methods were
also excluded.
This study was conducted in the Centro Médico Teknon
between May 2004 and November 2005. The study was
conducted in accordance with the Declaration of Helsinki
and received the local institutional review board and
Spanish Drug Agency (n°C03-0456) approvals. It has
been registered (NCT00497562) at ClinicalTrials.gov. All
patients gave written informed consent prior to their
inclusion in the study.
Treatment administration
The study medication is a human growth hormone pro-
duced by recombinant DNA technology in a mammalian
cell line (Saizen® 8 mg click easy, solution for injection).
Patients were randomly assigned, according to a compu-
ter-generated randomisation table, to receive either
0.0125 mg/kg/d of r-hGH subcutaneously added to stand-
ard intensive therapy or standard intensive therapy alone
during one year. Standard intensive therapy (adminis-
tered under stable conditions for at least 6 months before
inclusion) consisted of three oral administered drugs:
amitriptyline 10–50 mg/d, fluoxetine (or other SSRI 10–
40 mg/d) and tramadol 100–400 mg/d. These doses were
individually adjusted according to the associated pathol-
ogy in each case. Doses of r-hGH were adjusted after the
first month according to IGF-1 plasma levels and/or the
appearance of adverse events possibly related to GH.
Study Procedures
Prior to starting treatment administration, medical his-
tory, physical examination, selection criteria and
informed consent were recorded. Additionally, an insulin
tolerance test (ITT) and a cranial magnetic resonance
imaging (MRI) were performed at baseline visit at investi-
gator's discretion when IGF-1 levels were < 150 ng/mL (or
2 standard deviations below the mean value correspond-
ing to age and gender according to laboratory reference
values).BMC Musculoskeletal Disorders 2007, 8:119 http://www.biomedcentral.com/1471-2474/8/119
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Follow-up visits were scheduled at 1, 3, 6 and 12 months.
At baseline and follow-up visits, investigators determined
the number of tender points according to the ACR criteria
for fibromyalgia and patients self-completed the FIQ, the
EQ-5D, and a health-related Quality of Life Visual Ana-
logic Scale (VAS). A blood sample was drawn at baseline
and at follow-up visits to measure blood cell count, bio-
chemical profile and other laboratory assays including
GH, IGF-1, thyroid-stimulating hormone (TSH), thyrox-
ine (free T4), triiodothyronine (free T3), Estradiol (E2),
progesterone (P4), urinary free cortisol, insulinemia,
apolipoprotein B, C-reactive protein, erythrocyte sedi-
mentation rate, rheumatoid factor, aldolase and creatinki-
nase. Adverse events, concomitant medication and
treatment compliance were recorded at each follow-up
visit. A flow chart of the study procedures is shown in
Table 1.
Efficacy Assessments
The primary efficacy endpoint was the reduction in the
number of tender points at 12 months with respect to
baseline. Fibromyalgia trigger points were assessed by an
observer blind to the treatment group using the protocol
described by Wolfe et al. employing 18 (9 bilateral) stand-
ardized sites and according to ACR criteria [1]. Secondary
efficacy endpoints included the number of patients who
discontinued the study due to lack of efficacy, and the
completion of spanish validated versions of FIQ [13] and
the EQ-5D Quality of Life questionnaire [14] at baseline
and follow-up visits. The FIQ is a 10-item instrument with
good reliability and validity, that measures physical
impairment, wellbeing, missed work, pain, fatigue, rest,
stiffness, anxiety and depression [15]. The EQ-5D consists
of two parts; the Self-Questionnaire, which captures
respondent's descriptions of health problems on a 5-
dimensional classification of mobility, self-care, usual
activities, pain/discomfort and anxiety/depression, and
the EQ-VAS, which is a 20-centimeter visual analogue
scale where the respondent rates her health state today
between 0 (worst imaginable) and 100 (best imaginable).
The EQ-5D has been shown to be both reliable and valid
in adult patients with GH deficiency but also in multiple
musculoskeletal diseases [16].
Laboratory assays
Serum GH, IGF-1, TSH, free T4, free T3, E2, P4 and
insuline levels were determined by automated chemilu-
minescent immunoassay system using a commercially
available kit (IMMULITE® 2000, DPC, Los Angeles, CA).
The interassay coefficient of variation of GH and IGF-1
assays was 4.52% and 3.04%, respectively. The analytical
sensitivity of GH and IGF-1 assays was 0.05 ng/mL and
<25 ng/mL, respectively. Serum cortisol levels were also
determined by chemiluminiscence using the Liason Anal-
izer (Sorin Diagnostics S.pA, Italy).
Safety
Safety was assessed by the investigator through physical
examinations, including vital signs, haematological and
biochemical laboratory tests, reporting of adverse events,
Table 1: Study flow-chart
Visit 1
baseline
Visit 2
1 month
Visit 3
3 months
Visit 4
6 months
Visit 5
12 months
Data
Medical history X
Informed consent X
Demographic data X
Inclusion criteria X
Adverse events X X X X
Concomitant medication X X X X
Treatment compliance X X X X
Physical examination X X X
MRI (1) X
Laboratory assays X X X X X
IGF-1 levels (2) X X X X X
Insulin tolerance secretion test (3) X
Tender points evaluation X X X X X
Fibromyalgia Impact questionnaire X X X X X
EuroQol EQ-5D + VAS X X X X X
Rehabilitation X X X X X
Psychological assistance X X X X X
(1) When baseline IGF-1 < 150 ng/ml to exclude pituitary lesion.
(2) For patient inclusion and r-hGH dose adjustment.
(3) When IGF-1 < 150 ng/ml.BMC Musculoskeletal Disorders 2007, 8:119 http://www.biomedcentral.com/1471-2474/8/119
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and local tolerability. In order to minimize the occurrence
of adverse events, r-hGH doses were individually adjusted
during the study according to age-adjusted IGF-1 serum
levels (+ 2 standard deviation corresponding to 450 ug/
dL) and the investigator discretion.
Statistics
This was a pilot study with an exploratory goal. Thus, a
sample size was estimated to obtain preliminary results
that would allow evaluation for further possible investiga-
tions. Quantitative endpoints are presented as mean and
standard deviation (SD) or median and range. The 95%
confidence interval was used to indicate the precision of
an estimate. The homogeneity of variances was analysed
by a Levene's test and the within-group comparisons
employed t test and the non-parametric Mann-Whitney
Wilcoxon test when necessary. Categorical data are pre-
sented as absolute numbers and percentages. A Chi-
Square analysis or Fisher exact-test were used to compare
these variables when applicable.
Regarding the main variable, the differences between
groups were analyzed by analysis of covariance
(ANCOVA), with basal number of tender points as a cov-
ariate. The time course within-group comparisons were
analysed by repeated measurements analysis of variance
(ANOVA). All p values were based on a two-tailed distri-
bution, and 5% level of significance was considered. The
statistical analysis was based on Intention to Treat. The
SPSS statistical software package (version 12.0) was used
for statistical analysis.
Results
The study population included 24 women with a mean
age of 48.5 years, randomly assigned to r-hGH (n = 12) or
control (n = 12) groups. All patients fulfilled the ACR cri-
teria for fibromyalgia, the cut-off levels for severity (16/18
positive trigger points and FIQ>75) and duration of symp-
toms (>1 year), IGF-1 levels>250 ug/dL (three patients in
the control group had IGF-1<150 ug/dL and undergone
an ITT with a peak GH response above 5 ug/dL and had
normal MNR) and completed the study. GH levels were
normal and comparable in both groups. Baseline data are
shown in Table 2.
With regard to the primary efficacy outcome, the study
showed a reduction in the number of tender points (pairs)
in the r-hGH group compared to the control group, at 12-
month evaluation (p = 0.0001) (Figure 1). The mean (SD)
number of baseline tender points (pairs) was 8.75 (0.4) in
both treatment groups, and 3.25 (2.7) and 8.25 (0.9) in r-
hGH and control groups at 12 months, respectively. Sta-
tistically significant between-group differences were also
observed at 1, 3 and 6-month evaluations (p < 0.05) (Fig-
ure 1). Patients receiving r-hGH also had a within-group
improvement in the number of tender points (pairs),
Table 2: Baseline characteristics of 24 patients included in the study.
Data, mean (SD) r-hGH
(n = 12)
Control
(n = 12)
p value
t student test
Demographics
Age, years 47,4 (7,6) 49,6 (9,4) 0.555
Weight, kg 72,9 (12,3) 66,0 (9,4) 0.153
Waist, cm 89.2 (10.3) 76.6 (3.2) 0.01
BMI, Kg/m2 25,1 (5,3) 162,2 (5,9) 0.334
Fibromyalgia symptoms duration (prior study), months 21 (6) 23 (7) 0,204
Vital signs
Systolic blood pressure, mm Hg 124,8 (15,4) 117,5 (10,3) 0.222
Diastolic blood pressure, mm Hg 80,8 (6,6) 74,2 (7,9) 0.052
Heart rate, beats/min 75,8 (6,4) 77,9 (11,8) 0.721
Laboratory data
GH, ng/mL 0,4 (0,3) 0,9 (0,8) 0.134
IGF-1 g/L 173.3 (49.4) 98.6 (36.0) <0.001
TSH, µU/mL 1.3 (0.9) 1.3 (0.9) 0.998
free T4, ng/mL 3.3 (4.9) 5.5 (6.9) 0.433
free T3, pg/mL 3.7 (0.7) 2.9 (0.5) 0.041
Estradiol E2, pg/mL 117.8 (17.7) 98.4 (81.7) 0.708
P4, ng/mL 0.4 (0.3) 0.7 (0.3) 0.287
Urinary free cortisol, µg/24 h 98.2 (66.1) 44.5 (11.9) 0.030
Insulinemia U/dL 11.9 (14.7) 6.0 (2.7) 0.306
Apolipoprotein B, mg/L 102.8 (26.7) 98.7 (66.1) 0.744
C-Reactive protein, mg/L 3.2 (0.4) 3.5 (0.0) 0.417
Erythrocyte sedimentation rate, mm 12.8 (5.8) 11.0 (4.6) 0.482BMC Musculoskeletal Disorders 2007, 8:119 http://www.biomedcentral.com/1471-2474/8/119
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achieving statistical significance at all the follow-up visits
compared to baseline (p = 0.001). The control group
failed to achieve a significant within-group improvement
between baseline and 12-month evaluation. Figure 2
shows improvement in pain in each of the 9 bilateral trig-
ger point sites after 12 months for each treatment group.
Regarding the secondary endpoints, there were significant
differences between treatments favouring the r-hGH
group for the total FIQ score at 3, 6 and 12 months (p <
0.05) (Figure 3). The mean (SD) total FIQ score was 80.28
(4.0) and 79.23 (5.1) at baseline, and 43.57 (19.0) and
72.02 (9.0) at 12-month evaluation in the r-hGH and
control groups, respectively. Statistically significant
improvements compared to baseline appeared from
month 3 until the end of the study in the r-hGH group (p
= 0.001).
A statistical significant improvement was also observed in
r-hGH group (p < 0.05) in comparison to control group in
both pain and fatigue FIQ subscales. Thus, for the FIQ-
pain subscale, the mean (SD) was 8.67 (0.98) and 8.5
(1.09) at baseline, and 5.17 (2.44) and 7.75 (1.36) at 12-
month evaluation in the r-hGH and control groups,
respectively. A similar pattern of results was observed for
the FIQ-fatigue subscale, with a mean (SD) of 8.75 (1.6)
in both groups at baseline, and 4.92 (1.8) and 7.75 (1.2)
at 12-month evaluation in r-hGH and control groups,
respectively.
There were also significant differences between treatment
groups in terms of Quality of Life (EQ-5D). Thus, there
was a significant improvement in the mean VAS score for
the r-hGH group compared to control group at 1, 3, 6 and
12 months (p < 0.05), with a within-group significant
improvement from month 1 until the end of the study
compared to baseline (p = 0.001) (Figure 4). With regard
to the EQ-5D questionnaire, a similar trend was observed
in the mean weighted score with significant differences
between treatment groups at 1 and 3 months (p < 0.05)
and within-group significant improvement in the r-hGH
group from month 1 to the end of follow-up compared to
baseline (p = 0.017). The mean (SD) weighted score was -
0.04 (0.3) and 0.13 (0.2) at baseline, 0.79 (0.1) and 0.19
(0.4) at month 1, 0.74 (0.2) and 0.34 (0.4) at month 3,
and 0.62 (0.3) and 0.47 (0.3) at 12 month evaluation in
the r-hGH and control groups, respectively. It is worth
mentioning that there were differences between groups at
baseline in both EQ-VAS and EQ Self-Questionnaire, with
worse self-reported quality of life scores in the r-hGH
group compared to control group.
No withdrawals due to lack of efficacy were reported in
the study.
A statistically significant correlation between the increase
of IGF-1 serum levels and clinical improvement was
observed at the 1st month (p = 0.028). No further correla-
tion was observed with IGF-1 or any other biochemical
marker.
In terms of tolerability, no important changes in any of
the clinical or laboratory parameters were observed in any
of the treatment groups. No withdrawals due to adverse
events were reported in the study in any treatment group.
Despite the high r-hGH dosage (mean dose 0,123 mg/Kg/
d; range 0,8 mg- 1,4 mg), only 10 adverse events were
reported in 4 patients, all of them in the r-hGH group
(two cases each of joint pain, oedema and anemia and 1
case each of carpal tunnel syndrome, cholelithiasis, hyper-
triglyceridemia and hyperglycemia). No patient discon-
tinued the study due to adverse events. All reported
adverse events were considered to be possibly related to
the study treatment. All events were of mild intensity and
no serious adverse events were reported during the study.
Discussion
Fibromyalgia is a common syndrome of widespread mus-
culoskeletal pain. Although its etiology is not known,
there is evidence that fibromyalgia is influenced by several
factors, including alterations of autonomic nervous sys-
tem activity and HPA axis [6]. Growth Hormone secreted
by the pituitary acts on the liver and other tissues to stim-
ulate the production of IGF-1 [17]. Despite IGF-1 levels
are influenced by age, gender, nutrition, body mass index,
chronic stress and concomitant psychiatric medication,
and a low sensibility stays (between 37% and 48%, when
standardized by age and gender for a controlled popula-
tion) [18], a subset of fibromyalgia patients with low IGF-
Mean (CI) number of tender points Figure 1
Mean (CI) number of tender points. *p < 0.05 vs con-
trol group (ANCOVA); p = 0.001 time course within-group 
comparisons (repeated measures ANOVA) (statistical analy-
sis performed with values expressed as pairs of tender 
points).BMC Musculoskeletal Disorders 2007, 8:119 http://www.biomedcentral.com/1471-2474/8/119
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Percentage of patients with pain in each of the 9 bilateral tender point sites Figure 2
Percentage of patients with pain in each of the 9 bilateral tender point sites. *p < 0.05 vs control group (chi-square 
test).BMC Musculoskeletal Disorders 2007, 8:119 http://www.biomedcentral.com/1471-2474/8/119
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1 serum levels (cut-off 150 ug/dL for -2SD, as in our
study) but with normal insulin tolerance test has been
identified [7]. We hypothesize that this could be caused
by a low integrated GH secretion [8] together with a
hypersomatostatinergic tone [9].
The standard pharmacological therapy for this syndrome
includes the combination of tricyclic antidepressants,
SSRI and opioid analgesics [11]. Currently in fibromyalgia
patients with low IGF-1 serum levels, the administration
of r-hGH demonstrated efficacy as compared with pla-
cebo in a randomized, double-blind study [12]. However,
although other studies permitted the use of other medica-
tions, no homogeneous active-controlled GH add-on
studies have been performed to date in this population.
Taking into account this evidence, it seemed interesting to
conduct a study that evaluates the efficacy and safety of
low r-hGH doses added to standard therapy in the treat-
ment of severe (FIQ>75 and 16/18 positive trigger points)
and prolonged (>1 year) fibromyalgia patients with low
IGF-1 serum levels.
The present study is a prospective, randomized, open-
label, best available treatment-controlled clinical trial.
Even though no placebo group was included, the different
overall response observed between treatment groups, as
well as the intra-group differences in the r-hGH group as
compared with baseline, supports the internal validity of
this assay. The endpoints used in this study are well-vali-
dated outcome measures in the evaluation of fibromyal-
gia. The manual trigger point examination (in this case by
an observer blinded to the treatment) has been histori-
cally considered a key feature in the definition of fibromy-
algia . Likewise, the FIQ and EQ-5D have been widely
used in the clinical evaluation of this syndrome and GH
deficiency, respectivelly [3,16]. Other associated symp-
toms such as fatigue were evaluated with individual FIQ
subscales. The one-year duration of this study is longer
than the previous GH controlled trial (9 months) , thus
avoiding the seasonal variability of fibromyalgia symp-
toms. At the end of the study (12 months evaluation), the
mean number of tender points in the r-hGH group
showed a reduction of 60% compared to the control
group and 63% compared to baseline (p < 0.05 in both
comparisons). Similar results were observed at the same
time-point assessment in the FIQ, with a mean score
reduction of 39.5% compared to control group and
45.7% compared to baseline (p < 0.05 for both compari-
sons). This global FIQ score improvement in the GH
group is the result of a similar improvement in all the spe-
cific subscales (fatigue, pain, professional activity, tender-
ness, anxiety, depression, morning weakness, global well-
being, laboral absenteeism, and physical dysfunction).
Regarding the quality of life self-assessment, the VAS eval-
uation showed a similar trend, with a 38.7% mean score
improvement at 12 months in the r-hGH group versus
control group and 64.9% versus baseline (p = 0.001 in
both comparisons). The weighted score assessment of the
EQ-5D questionnaire at the end of the study compared to
baseline showed a mean change of 0.59 and 0.33 in r-
hGH and control groups, respectively. This change from
baseline achieved statistical significance in the r-hGH
group (p = 0.017).
It is important to mention the prompt response in the r-
hGH group, evidenced and maintained since the first
month assessment. In our study all 12 patients in the r-
hGH group experienced global improvement and 1
patient even scored 100 in the VAS scale at the end of the
study. This contrasts favourably with Bennett's previous
study [12] where only 15 out of 22 patients in the GH
treatment group experienced improvement. The differ-
ence in success rates could possibly be explained by the
Mean (CI) score of EQ-VAS Figure 4
Mean (CI) score of EQ-VAS. *p < 0.05 vs control group 
(ANCOVA); p = 0.001 time course within-group compari-
sons (repeated measures ANOVA).
Mean (CI) total score of Fibromyalgia Impact Questionnaire Figure 3
Mean (CI) total score of Fibromyalgia Impact Ques-
tionnaire. *p < 0.05 vs control group (ANCOVA); p = 
0.001 time course within-group comparisons (repeated 
measures ANOVA).BMC Musculoskeletal Disorders 2007, 8:119 http://www.biomedcentral.com/1471-2474/8/119
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greater basal homogeneity in the present study regarding
duration and severity (FIQ ≥ 75; >16/18 positive trigger
points) of disease, active and concomitant pharmacologi-
cal treatment, together with active rehabilitation and psy-
chological assistance. The lack of correlation between IGF-
1 and markers of clinical improvement may be due in part
to the step-down r-hGH dose adjustments performed in
order to avoid adverse events, and in part due to the unex-
pected statistical difference seen in IGF-1 levels. These dif-
ferences in a small number group are due to 3 patients in
the control group with values lower than 150 ug/dL (who
had an ITT and MNR for this reason). IGF-1 was consid-
ered as a dyctomic variable at inclusion, not as a continu-
ous one, therefore we cannot expect it to be a predictor
marker of response.
The concomitant administration of r-hGH and standard
therapy was well tolerated. No important changes in any
of the clinical or laboratory parameters were observed in
the two groups. A total of 10 adverse events were reported
in 4 patients, all of them in the r-hGH group. However,
only one (8.3%) carpal tunnel syndrome was described in
comparison with the 7 cases (31.8%) reported in the GH
treatment group in Bennett's previous study [12] despite
the fact that both administered 0.0125 mg/kg/d of r-hGH.
There was 1 case of hyperglycemia at the 1st month follow-
up vist, which was normalized at the 3rd month evaluation
after reducing the dose by 0.02 mg/d. No patients discon-
tinued the study due to r-hGH related adverse events. No
control group dropouts were seen, possibly due to the
intense standard treatment received (pharmacological,
psychological and rehabilitation).
Conclusion
The present study suggests the advantage of adding a
0.0125 mg/Kg r-hGH daily dose to the standard therapy
versus the standard therapy alone in a subset of severe
fibromyalgia patients with low IGF-1 serum levels. Obvi-
ously, the results of this study should be viewed in light of
the methodological limitations, such as the open assign-
ment to the study drug, the lack of a placebo group and
the small sample size. However, the consistency and mag-
nitude of these results, obtained in this well-characterized
sample and with long-term treatment period, added to the
similar trend observed in the previous placebo-controlled
study, are encouraging and warrant further validation in a
multicenter, double-blind confirmatory study which is
currently ongoing.
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